Drug intelligence / Profile preview

SDGR-8139

Development stage: Preclinical
Lead developer: Schrödinger
Modality: Small Molecules
Administration: Oral

Overview

SDGR-8139 is an early-stage, oral small molecule cytokine inhibitor originally developed by Schrödinger and subsequently licensed to Tectora Therapeutics, a biotechnology company co-founded by Schrödinger, New Enterprise Associates (NEA), and RA Capital Management. The program is designed to target immune-mediated diseases, specifically focusing on immunology and inflammation. Tectora plans to leverage Schrödinger's physics-based computational drug discovery platform to advance SDGR-8139 toward clinical candidate status.

Beyond the preview

Go deeper on SDGR-8139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDGR-8139.

Explore the full profile